CLNN Stock Forecast & Price Target

Clene is well positioned because FDA Type C feedback indicated CNM-Au8’s existing ALS dataset may support an NDA under the accelerated approval pathway, with NfL acknowledged as a potentially acceptable surrogate endpoint and filing targeted for Q3 2026. The case is strengthened by repeated biomarker and survival signals, including statistically significant NfL and GFAP declines, correlations between biomarker reductions and lower mortality risk, and sustained survival benefits in HEALEY ALS analyses. Financially, the company also benefits from up to $8.0 million in third-year NIH subaward funding through August 2026 under a broader $45.1 million grant, which adds non-dilutive capital and supports execution into the planned Q1 2027 confirmatory trial.

Clene is a high-risk clinical-stage company whose value depends almost entirely on CNM-Au8 advancing through uncertain neurodegenerative disease trials, where failed or inconclusive data could erase much of the assumed upside. The excerpt itself highlights only 15% probability of success for both ALS and MS, reflecting steep development uncertainty, limited regulatory visibility, and a difficult path to market across a field with historically high treatment failure rates. Financially, the company also faces material funding risk, including possible dilutive capital raises, while its valuation relies on future U.S. and ex-U.S. opportunities that currently remain unproven.